Open Access
Med Sci (Paris)
Volume 38, Number 1, Janvier 2022
Page(s) 45 - 51
Section M/S Revues
Published online 21 January 2022
  1. Jellinger KA. Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) 2009 ; 116 : 1111–1162. [CrossRef] [PubMed] [Google Scholar]
  2. Sakamoto M, Uchihara T, Hayashi M, et al. Heterogeneity of nigral and cortical Lewy bodies differentiated by amplified triple-labeling for alpha-synuclein, ubiquitin, and thiazin red. Exp Neurol 2002 ; 177 : 88–94. [CrossRef] [PubMed] [Google Scholar]
  3. Bourdenx M, Koulakiotis NS, Sanoudou D, et al. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Prog Neurobiol 2017 ; 155 : 171–193. [CrossRef] [PubMed] [Google Scholar]
  4. Bartels T, Choi JG, Selkoe DJ. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011 ; 477 : 107–110. [CrossRef] [PubMed] [Google Scholar]
  5. Robustelli P, Piana S, Shaw DE. Developing a molecular dynamics force field for both folded and disordered protein states. Proc Natl Acad Sci U S A 2018 ; 115 : E4758–E4E66. [CrossRef] [PubMed] [Google Scholar]
  6. Schor M, Mey A, MacPhee CE. Analytical methods for structural ensembles and dynamics of intrinsically disordered proteins. Biophys Rev 2016 ; 8 : 429–439. [CrossRef] [PubMed] [Google Scholar]
  7. Raskatov JA, Teplow DB. Using chirality to probe the conformational dynamics and assembly of intrinsically disordered amyloid proteins. Sci Rep 2017 ; 7 : 12433. [CrossRef] [PubMed] [Google Scholar]
  8. Buell AK, Dobson CM, Knowles TP. The physical chemistry of the amyloid phenomenon: thermodynamics and kinetics of filamentous protein aggregation. Essays Biochem 2014 ; 56 : 11–39. [CrossRef] [PubMed] [Google Scholar]
  9. De Giorgi F, Laferriere F, Zinghirino F, et al. Novel self-replicating alpha-synuclein polymorphs that escape ThT monitoring can spontaneously emerge and acutely spread in neurons. Sci Adv 2020; 6. [Google Scholar]
  10. Peelaerts W, Bousset L, Van der Perren A, et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015 ; 522 : 340–344. [CrossRef] [PubMed] [Google Scholar]
  11. Dehay B, Bourdenx M, Gorry P, et al. Targeting alpha-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol 2015 ; 14 : 855–866. [CrossRef] [PubMed] [Google Scholar]
  12. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003 ; 24 : 197–211. [CrossRef] [PubMed] [Google Scholar]
  13. Goedert M.. NEURODEGENERATION. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 2015 ; 349 : 1255555. [CrossRef] [PubMed] [Google Scholar]
  14. Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 2008 ; 14 : 504–506. [CrossRef] [PubMed] [Google Scholar]
  15. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 2008 ; 14 : 501–503. [CrossRef] [PubMed] [Google Scholar]
  16. Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci 2016 ; 17 : 251–260. [CrossRef] [PubMed] [Google Scholar]
  17. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 2013 ; 14 : 38–48. [CrossRef] [PubMed] [Google Scholar]
  18. Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012 ; 338 : 949–953. [CrossRef] [PubMed] [Google Scholar]
  19. Osterberg VR, Spinelli KJ, Weston LJ, et al. Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep 2015 ; 10 : 1252–1260. [CrossRef] [PubMed] [Google Scholar]
  20. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011 ; 72 : 57–71. [CrossRef] [PubMed] [Google Scholar]
  21. Mougenot AL, Nicot S, Bencsik A, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2012 ; 33 : 2225–2228. [CrossRef] [PubMed] [Google Scholar]
  22. Arotcarena ML, Dovero S, Prigent A, et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain 2020; 143 : 1462–75. [CrossRef] [PubMed] [Google Scholar]
  23. Bourdenx M, Nioche A, Dovero S, et al. Identification of distinct pathological signatures induced by patient-derived alpha-synuclein structures in nonhuman primates. Sci Adv 2020; 6 : eaaz9165. [CrossRef] [PubMed] [Google Scholar]
  24. Chu Y, Muller S, Tavares A, et al. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain 2019 ; 142 : 3565–3579. [CrossRef] [PubMed] [Google Scholar]
  25. Recasens A, Dehay B, Bove J, et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014 ; 75 : 351–362. [CrossRef] [PubMed] [Google Scholar]
  26. Del Tredici K, Rub U, De Vos RA, et al. Where does parkinson disease pathology begin in the brain?. J Neuropathol Exp Neurol 2002 ; 61 : 413–426. [CrossRef] [PubMed] [Google Scholar]
  27. Attems J, Jellinger KA. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease. Neuropathol Appl Neurobiol 2008 ; 34 : 466–467. [CrossRef] [PubMed] [Google Scholar]
  28. Zaccai J, Brayne C, McKeith I, et al. Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology 2008 ; 70 : 1042–1048. [CrossRef] [PubMed] [Google Scholar]
  29. Adler CH, Beach TG. Neuropathological basis of nonmotor manifestations of Parkinson’s disease. Mov Disord 2016 ; 31 : 1114–1119. [CrossRef] [PubMed] [Google Scholar]
  30. Surmeier DJ, Obeso JA, Halliday GM. Parkinson’s Disease Is Not Simply a Prion Disorder. J Neurosci 2017 ; 37 : 9799–9807. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.